AV Therapeutics

AV Therapeutics — Investor Presentation (June 2015)

15 slides from AV Therapeutics's investor presentation, Jun 25, 2015

  1. Slide 1: Safe Harbor Statement

    Slide 1: Safe Harbor Statement

    Safe Harbor Statement This presentation includes “forwardooking statements” as defined by the Securities and Exchange Commission, These statements generally concern our plans, expectations and objectives for future operations, All statements, other than statements of historical facts, included in th

  2. Slide 2: 1 in 6 American men will be diagnosed with Prostate Cancer

    Slide 2: 1 in 6 American men will be diagnosed with Prostate Cancer

    1 in 6 American men will be diagnosed with Prostate Cancer AKKKEK at an annual cost of 30,000 lives and $15B CAPRIDINE is a breakthrough in the treatment of late stage prostate cancer v Achieved success with animal tests v Reviewed and recognized by industry leading advocates v Ready to enter clinic

  3. Slide 3: AV Therapeutics' Mission

    Slide 3: AV Therapeutics' Mission

    AV Therapeutics’ Mission *Develop advanced cancer and infectious diseases therapies «License to Big Pharma: leverage their production, distribution & marketing *Create high EPS operation for inside and outside stakeholders

  4. Slide 4: The need is so great...

    Slide 4: The need is so great...

    The need is so great... Other than skin cancer, prostate cancer is the most common cancer in American men. + 233,000 cases of prostate cancer will be diagnosed in the U.S. every year * Almost 30,000 will die We have not found acceptable treatments") = Only 5 drugs are FDA-approved * High Toxicity —

  5. Slide 5: ..even marginal remedies make lots of money!

    Slide 5: ..even marginal remedies make lots of money!

    ..even marginal remedies make lots of money! We spend $100B on cancer treatments annually * $15B on prostate cancer alone, of which $8B is on drugs * One small prostate cancer drug company has a $9B market cap! Imagine the value of effective treatment!

  6. Slide 6: Capridine is a Major Advance in Prostate Cancer Treatment

    Slide 6: Capridine is a Major Advance in Prostate Cancer Treatment

    Capridine is a Major Advance in Prostate Cancer Treatmen' Capridine kills both hormone sensitive and insensitive cells, with 3 unique and powerful features: * High therapeutic index (small dose yields high impact) * Low blood and bone marrow toxicity (reducing side effects) * Re-enables previous dru

  7. Slide 7: ..and is Spring-Loaded to Begin Clinical Trials

    Slide 7: ..and is Spring-Loaded to Begin Clinical Trials

    ..and is Spring-Loaded to Begin Clinical Trials 1. Successful animal tests 2. Reviewed by recognized medical advocates — NIH, NCI, renowned hospitals and doctors 3. Ready for Phase 1 trials with arrangements for world class institutions in the U.S. and Canada

  8. Slide 8: Great scientists, astounding science,

    Slide 8: Great scientists, astounding science,

    Great scientists, astounding science, Now supported by experienced mgmt & stakeholder care

  9. Slide 9: New Offensive Line: Professional Services

    Slide 9: New Offensive Line: Professional Services

    me Superbowl Backfiel low a New Offensive Line Professional Services Investor Relations slim Hock, Hanover International SEC Counsel Gorald Adler, Newman & Mottison LLP Transfer Agent Seth Farbman, VStock Transfer Accounting Rosenborg & Chesnov Gov't Relations R. Gardner, New World Technology Partne

  10. Slide 10: Intellectual Property/Product Development Engine

    Slide 10: Intellectual Property/Product Development Engine

    Intellectual Property/Product Development Engine AVT’s first two featured patents!) 1. Capridine - active drug for early and late stage prostate cancer 2. Provax - preventative vaccine for prostate cancer reoccurrence Do not expire until 2021 and may be extended (1)Patents also exist in EU, Canada,

  11. Slide 11: Laboratory Pipeline

    Slide 11: Laboratory Pipeline

    aboratory Pipeline * 9-alkylamino-1-nitroacridine derivatives (Capi + United States Patent # 6,589,961 * Nitroacridine tumor inhibitor composition + United States Patent #7,622,47882 * Immunotherapy for prostate cancer using recombinant bacille Calmette-Guerin expressing prostate specific antigens +

  12. Slide 12: Quick to Market, Low Risk Strategy

    Slide 12: Quick to Market, Low Risk Strategy

    Quick to Market, Low Risk Strategy Post revenue within 18 months of entry into phase | trials: * We develop, test and begin clinical trials for new products * Establishment pharma licensee completes FDA approvals and arranges production and distribution | ; ; Design Animal Trials Licensee VT Activit

  13. Slide 13: Financial Model Features High Revenue, Low Operating Cost

    Slide 13: Financial Model Features High Revenue, Low Operating Cost

    Financial Model Features High Revenue, Low Operating Cost At 15% market share, Capridine is worth $8B to Big Pharma * AVT license fee and royalty could post $250M over 7 years * Virtually all profit, since AVT has no production, distribution or marketing expense Provax, which is the first of its kin

  14. Slide 14: Fact Sheet

    Slide 14: Fact Sheet

    Fact Sheet Intellectual Property * Capridine (patente) - breakthrough in prostate cancer treatment ¥ Successful animal tests and NCI review Appears to be active for Colon Cancer as well ¥ Following of recognized medical advocates — NIH, NCI, renowned hospitals and doctors ¥ Ready for Phase 1 trials

  15. Slide 15: Key Success Factors

    Slide 15: Key Success Factors

    Key Success Factors 1. Growing, unsatisfied market 2. Protected Intellectual Property; new technology pipeline 3. FDA clinical trial experience 4. Re-aligned, experienced leadership & support team 5. High Margin, quick to market business model

Source: SEC EDGAR · 8-K filed Jun 25, 2015

More decks from AV Therapeutics